本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 登录新浪财经APP 搜索【信披】查看更多考评等级 股东华邦生命健康股份有限公司保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示： 1、本次权益变动主体为持有山东凯盛新材料股份有限公司（以下简称"凯盛新材"、"上市公司"或"公 司"）5%以上股份的股东华邦生命健康股份有限公司（以下简称"华邦健康"或"出让方"）。本次权益变 动方式为被动稀释、询价转让，本次权益变动后，出让方拥有权益的股份占公司总股本的比例由 44.51%下降至39.75%（以下简称"本次权益变动"），权益变动触及5%的整数倍。 2、本次询价转让出让方为凯盛新材控股股东，本次权益变动不会导致上市公司控股股东及实际控制人 发生变化，不会对公司治理结构及持续经营产生重大影响。 3、本次询价转让为非公开转让的询价转让方式，不会通过集中竞价交易方式进行，不触及要约收购。 受让方通过询价转让受让的股份，在受让后6个月内不得转让。 4、出让方询价转让股份数量为20,000,000股，占公司总股本的4.75%；询价转让的价格为13.69元/股， ...

2、经自查，本公司前期所披露的信息，不存在需要更正、补充之处。 3、经自查，本公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生较大影响的未公 开重大信息。 4、经自查，本公司已披露的经营情况、内外部经营环境未发生重大变化。 一、股票交易异常情况 山河智能装备股份有限公司（证券简称：山河智能；证券代码：002097；以下简称"公司"）股票于2025 年7月22日、2025年7月23日连续二个交易日收盘价格涨幅偏离值累计超过20%，根据《深圳证券交易所 交易规则》的相关规定，属于股票交易异常波动的情况。 二、公司关注、核实情况说明 针对公司股票交易异常波动，公司董事会对有关事项进行了核查，并发函向控股股东及实际控制人就相 关事项进行了核实，现就有关情况说明如下： 1、经核查，公司、控股股东和实际控制人在股票异常波动期间不存在买卖公司股票的行为。 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 特此公告。 山河智能装备股份有限公司 5、经核查，公司、控股股东和实际控制人不存在关于本公司的应披露而未披露的 ...

Group 1 - The company's stock price experienced an abnormal fluctuation, with a cumulative increase of over 20% in closing prices over two consecutive trading days (July 22 and July 23, 2025) [1] - The company conducted an internal review and confirmed that there were no corrections or supplements needed for previously disclosed information [1][4] - The company has not identified any significant undisclosed information that could impact its stock price, and its operations remain normal without major changes in the internal or external business environment [1][4] Group 2 - The company's controlling shareholders and actual controllers did not engage in buying or selling the company's stock during the period of abnormal trading [2] - The company confirmed that there were no violations of fair information disclosure [3][5] - The company will strictly adhere to legal and regulatory requirements for information disclosure and will ensure timely communication of relevant information [6]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688392 证券简称：骄成超声公告编号：2025-033 上海骄成超声波技术股份有限公司 第二届董事会第九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海骄成超声波技术股份有限公司（以下简称"公司"）第二届董事会第九次会议于2025年7月23日以现 场结合通讯表决的方式召开。本次会议通知以及相关材料已于2025年7月20日以邮件方式送达公司全体 董事。本次会议由周宏建先生主持，应出席会议董事5名，实际出席会议董事5名。本次会议的召集、召 开符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的有关规定。 二、董事会会议审议情况 (一)审议通过《关于变更注册资本、取消监事会、修订〈公司章程〉并办理工商变更登记的议案》 鉴于公司2024年限制性股票激励计划首次授予部分第一个归属期归属股份合计933,360股已完成归属并 上市流通，公司注册资本由114,800,000元变更为115,733,360元、股份总数由114, ...

Group 1 - The company completed the issuance of its 2025 seventh short-term financing bond on July 22, 2025 [2] - The relevant documents for the bond issuance have been published on the China Money website and the Shanghai Clearing House website [2] - The company guarantees that the information disclosed is true, accurate, and complete, with no false records or misleading statements [1][4] Group 2 - The company issued its 2025 first short-term financing bond on January 15, 2025, with an issuance amount of RMB 1 billion and a coupon rate of 1.73% [4] - The bond had a maturity period of 188 days, with the repayment date set for July 22, 2025 [4] - On July 22, 2025, the company repaid the principal and interest of the first short-term financing bond, totaling RMB 1,008,910,684.93 [5]

登录新浪财经APP 搜索【信披】查看更多考评等级 重要提示 1、景顺长城中证芯片产业交易型开放式指数证券投资基金发起式联接基金经中国证监会证监许可 【2025】1453号文准予募集注册。中国证监会对本基金的注册并不代表中国证监会对本基金的风险和收 益做出实质性判断、推荐或者保证。 2、本基金为股票型发起式证券投资基金、ETF联接基金。 3、本基金的管理人和登记机构为景顺长城基金管理有限公司（以下简称"本公司"），基金托管人为国 投证券股份有限公司（以下简称"国投证券"）。 4、本基金的发售对象为符合法律法规规定的可投资于证券投资基金的个人投资者、机构投资者、发起 资金提供方、合格境外投资者以及法律法规或中国证监会允许购买证券投资基金的其他投资人。 5、景顺长城中证芯片产业交易型开放式指数证券投资基金发起式联接基金（以下简称"本基金"）基金 份额将于2025年7月28日至2025年7月30日通过本公司直销中心和其他销售机构网点公开发售。 6、投资者欲购买本基金，需开立本公司基金账户。基金募集期内本公司直销中心和指定销售网点同时 为投资者办理开立基金账户的手续。在基金募集期间，投资者的开户和认购申请可同时办理。 ...

Group 1 - The core point of the announcement is that Chengdu Santuo Biotech Co., Ltd. has received the drug registration certificate for Ganirelix Injection from the National Medical Products Administration, which is a significant milestone for the company [1][3]. - The drug is classified as a chemical drug of category 4 and is intended for use in women undergoing controlled ovarian stimulation in assisted reproductive technology to prevent premature luteinizing hormone (LH) surges [2][3]. - The approval of Ganirelix Injection will enhance the company's product pipeline in injectable medications and improve its market competitiveness in the assisted reproduction sector, positively impacting its business development [3].

Core Points - The company, in a consortium with Zhejiang Guofeng Group Co., Ltd. and Zhejiang University Architectural Design Institute Co., Ltd., has won the bid for the "Qianjiang Century City Intelligent Comprehensive Sci-tech Park EPC General Contracting" project with a total bid amount of RMB 1,182.85 million [1][2] - The project has a total planned investment of RMB 3.956 billion and a total construction area of 273,600 square meters, including 213,000 square meters above ground and 59,000 square meters underground [2] - The project will take 1,080 calendar days to complete and consists of 11 independent buildings, with the tallest building being a 150-meter high super-tall R&D center [2] Impact on the Company - Winning this project will facilitate the company's transition from a steel structure subcontractor to a general contractor, aligning with its "EPC General Contracting + No. 1 Project" dual-engine development strategy, thereby enhancing its brand influence in the industry [3] - The total bid amount represents 10.52% of the company's audited revenue for the fiscal year 2024, indicating a significant potential positive impact on future operations [3]

Group 1 - The company held its 29th meeting of the third board of directors on July 22, 2025, with all 7 directors present [2][5] - The board approved the proposal to lease idle factory buildings to enhance asset utilization and generate rental income [4][11] - The proposal to change the business scope and amend the company's articles of association was also approved [7][16] Group 2 - The company plans to lease approximately 30,500 square meters of idle factory space located at 420 Anwen Road, Jinhua City, Zhejiang Province [11] - The rental terms will be determined based on market conditions, and the board will be authorized to finalize the leasing details [11] - The leasing does not constitute a related party transaction or a major asset restructuring [11] Group 3 - The company aims to improve asset efficiency and financial performance through this leasing initiative [13] - The board proposed to convene the first extraordinary general meeting of 2025 to discuss the approved proposals [9][19] - The extraordinary general meeting is scheduled for August 8, 2025, at 15:00 [21][26]

Group 1 - The company has signed a maximum mortgage contract with Fujian Pizaihuang Cosmetics Co., Ltd. to provide a guarantee of up to 8 million yuan for its subsidiary Hangzhou Chuanghua's 2024 annual distribution contract [2] - Hangzhou Chuanghua has fully settled the guaranteed account period under the mortgage contract by December 24, 2024, and the mortgage was officially released on June 23, 2025 [2] - The company approved a new mortgage guarantee for Hangzhou Chuanghua for the 2025 annual distribution contract with Pizaihuang, with the same maximum guarantee amount of 8 million yuan [3] Group 2 - The mortgage property is a non-residential real estate located at No. 51, Binhai West Road, Taiyuan City, Shanxi Province [3] - Hangzhou Chuanghua and its shareholder, KunTing Technology, provided counter-guarantees for the company's mortgage [2][3] - The company has completed the necessary mortgage registration procedures as required by the relevant agreements [3]